Core Insights - Shanghai Tengmai Pharmaceutical Technology Co., Ltd. has completed an A+ round financing, raising $22 million, with participation from several investment firms [1][2]. Financing Details - The financing round took place on November 13, 2025, with a total amount of $22 million [2]. - Participating investors include Yicun Capital, Xinneng Venture Capital, Aobo Capital, Qiming Venture Partners, Chengwei Capital, and HongShan Sequoia China [1][2]. Company Overview - Tengmai Pharmaceutical is a drug molecule discovery platform that combines proprietary quantum mechanics-based and AI-driven high-performance computing with scalable and efficient wet laboratories to provide a one-stop solution [2]. - The company aims to enhance the speed of drug molecule discovery and reduce R&D costs through its networked high-performance computing platform and computational power [2].